

# Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10 **Characterization of multiple constituents in rat plasma after oral administration of Shengmai San using**  
11 **ultra-performance liquid chromatography coupled with electrospray ionization/quadrupole-time-of-flight**  
12 **high-definition mass spectrometry**  
13  
14  
15  
16  
17  
18  
19  
20

21 Ying Han, Fangfang Wu, Aihua Zhang, Hui Sun, Wenfeng Wei, Xijun Wang

22 National TCM Key Laboratory of Serum Pharmacology, Laboratory of Chinmedomics and Metabolomics,  
23 Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Heping Road, Harbin, China  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53  
54  
55 **\*Correspondence**  
56

57 Prof. Ying Han and Xijun Wang

58 National TCM Key Laboratory of Serum Pharmacology

59 Laboratory of Chinmedomics and Metabolomics

60 Department of Pharmaceutical Analysis

Heilongjiang University of Chinese Medicine

Heping Road 24

Xiangfang District

Harbin 150040, China.

Tel. & Fax +86-451-86053141

Email: tcmomics@163.com

**Abstract**

Shengmai San (SMS), a well-known traditional Chinese medical formula containing seven herbal medicines, has been used for the treatment of cardiovascular disease in Asian, however, its active chemical constituents remain perfectly unclear so far. To quickly identify the chemical constituents of SMS and to understand the chemical profiles related *in vivo* activity of SMS, a rapid and robust ultra-performance liquid chromatography coupled with electrospray ionization/quadrupole-time-of-flight high-definition mass spectrometry (UPLC-Q-TOF-HDMS) approach has been applied for online identification of multiple components in rat plasma after oral administration of SMS. Metabolynx software that was a novel post-acquisition data processing software to detect components, was also conducted to discover bioactive components *in vivo*. A total of 30 compounds were detected in dosed rat plasma compared with blank rat plasma and tentatively characterized by comparing their retention times and MS spectra with those of authentic compounds or literature data. Furthermore, this work demonstrated the possibilities of using UPLC-Q-TOF-HDMS approach for identification of bioactive compounds from herbal medicines *in vivo*. Our present results also proved that the established method could provide helpful chemical information for further pharmacological studies of SMS.

**Keywords:**

UPLC-Q-TOF-MS/MS, Metabolynx, herbal medicines, multiple constituents, Shengmai San

## Introduction

Traditional Chinese Medicine (TCM), an essential part of the healthcare system in most Asian countries, is increasingly being used in Western medicine [1]. Presently, there are no formal analytical methods for the identification of the chemicals in TCM. The ability to measure the multiple constituents from the herbal formulae are critical in understanding of the action of TCM [2-7]. *Shengmai San* (SMS), which was first recorded in “*Yi Xue Yuan Li*” and, is one of the most famous Chinese herbal formulae, consists of *Panax ginseng*, *Ophiopogon japonicas* and *Schisandra chinensis* with dosage proportion of 5:3:1.5 [8,9]. Previous studies in our laboratory have demonstrated that a total of 92 compounds were identified by comparing the accurate mass and fragments information with that of the authentic standards as well as by MS analysis and the correlative references data. These constituents included ginsenosides, lignans, steroidal saponins and homoisoflavanones [10]. Comparing with the previous studies, our research detected more compounds and presented more rapid [11]. These studies only emphasized on the chemical components *in vitro*, while which ingredient absorbed into the blood is unclear. UPLC have greatly improved the resolution, sensitivity and analytical speed, integrating with MS to form a robust platform for TCM research [12-14].

Rapid identification and structural elucidation of the chemical constituents in the TCM formulae and rat plasma may provide important experimental data for further pharmacological and clinical research [15]. Major constituents in the single herbs of SMS have been well studied, however, to the best of our knowledges, the *in vivo* chemical constituents in SMS has not been completely investigated so far. Therefore, in the present study, UPLC-Q-TOF-HDMS analysis was firstly developed to systematic investigation of the chemical components of SMS *in vivo*, which gave the accurate molecular weights and the fragmentation patterns acquiring from multi-stage mass fragmentation by Metabolynx<sup>TM</sup> analyzer for comprehensive understanding of the multiple absorbed components in rat plasma after oral administration of SMS.

## 2. Experimental

### 2.1 Chemicals and reagents

Leucine enkephalin was purchased from Sigma–Aldrich (MO, USA). Other reagents and chemicals were of analytical grade. Formic acid and phosphoric acid (analytical grade) was purchased from the Beijing Reagent Company (Beijing, China). Acetonitrile and methanol (HPLC grade) was purchased from Merck (Darmstadt, Germany). Deionized water was purified on a Milli-Q system (Millipore, Bedford, USA). The *Panax ginseng*, *Ophiopogon japonicas* and *Schisandra chinensis* were purchased from the Harbin Shiyitang Drugstore and were authenticated by Professor Xijun Wang of the Department of Pharmacognosy, Heilongjiang University of Chinese Medicine.

### 2.2. Animals

Male Wistar rats (250±20 g) were provided by the Laboratory Animal Center of Heilongjiang University of Chinese Medicine (Harbin, China). Rats were bred in a breeding room with temperature of 24±2 °C, humidity of 60±5%, and 12 h

1  
2  
3  
4 dark-light cycle. They were given access to tap water and normal chow *ad libitum*. All the experiment animals were housed  
5  
6  
7 under the above conditions for 7 days acclimation, and were fasted overnight before the experiments. The animal facilities  
8  
9 and protocols were approved by the Institutional Animal Care and Use Committee, Heilongjiang University of Chinese  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 2.3. Preparation of SMS samples for analysis

SMS sample was prepared by combining the *Panax ginseng*, *Ophiopogon japonicas* and *Schisandra chinensis*. Then the mixture was extracted three times with 1000 mL, 800 mL and 600 mL water for 1 h, respectively. The extracts were combined and concentrated to approximate 0.8 g/mL, and this concentration solution was used for oral administration. All sample solutions were stored at  $-20\text{ }^{\circ}\text{C}$  and used at room temperature.

### 2.4 Preparation of plasma sample for analysis

Freeze-dried powder of SMS was dissolved with distilled water as stock solution (0.8g/mL), and was orally administrated to male Wistar rats (1mL/100g body weight), and the control rats were orally administered with physiological saline in the same way [16]. One hour after drug administration, the animals were anaesthetized by intraperitoneal injection of 1% pentobarbital sodium (0.15mL/100g body weight). The 5 mL blood was collected from the hepatic portal vein and then centrifuged at 13 000 rpm for 10 min at  $4\text{ }^{\circ}\text{C}$ . All plasma samples from one group of rats were combined into one sample to eliminate the individual variability. The plasma samples were pretreated by solid phase extraction before LC/MS analysis. The 1mL plasma was processed on a pre-activated OASIS HLB solid phase extraction  $\text{C}_{18}$  column(30 $\mu\text{m}$ , 60mg, Waters Corporation, USA), washed with 4 mL of water and 2 mL of 20% methanol and abandoned the eluents, then eluted with 3 mL of 100% methanol. The 100% methanol eluents were collected and dried under nitrogen gas at  $35\text{ }^{\circ}\text{C}$ . The residues were redissolved in 100  $\mu\text{L}$  of methanol and then centrifuged at 13 000 rpm for 10 min at  $4\text{ }^{\circ}\text{C}$ . The 3 $\mu\text{L}$  supernatant obtained was finally used as UPLC-Q-TOF-HDMS samples.

### 2.5 UPLC-Q-TOF-HDMS analysis

**2.5.1 Liquid Chromatography Conditions**—UPLC was performed with a Waters ACQUITY UPLC<sup>TM</sup> system (Waters Corporation, Milford, USA), equipped with quaternary pump, vacuum degasser, autosampler, diode-array detector. The chromatography was performed on a Waters ACQUITY HSS  $\text{T}_3$  column (2.1mm $\times$ 100mm, 1.8 $\mu\text{m}$ ). The column temperature was maintained at  $45\text{ }^{\circ}\text{C}$ . The mobile phase consisted of (A) 0.01% formic acid in water and (B) ACN containing 0.01% formic acid used gradient elute procedure as follows: 0-2.5min, A 1-20%; 2.5-5.5min, A 20-32%; 5.5-8.5min, A 32-43%; 8.5-12.5min, A 43-55%; 12.5-20 min; 55-99 %. The flow rate was 0.50 mL/min and 3  $\mu\text{L}$  aliquot of each sample was injected into the column.

**2.5.2 Mass Spectrometry Detection**—Waters Micromass Q-TOF-micro<sup>TM</sup> Synapt High Definition Mass Spectrometer (Manchester,UK) equipped with electrospray ion source operating in positive ion and negative ion mode. For the UPLC-Q-TOF-HDMS analysis, the optimal conditions were as follows: In positive ion mode, the source temperature was

1  
2  
3  
4 set at 105 °C with a cone gas flow of 50 l/h, a desolvation gas temperature of 350 °C and a desolvation gas flow of 600 l/h,  
5  
6 the capillary voltage was set at 2400 V, the sample cone voltage was set at 35 V and the extraction cone voltage was set at  
7  
8 3.0 V. In negative ion mode, the source temperature was set at 115 °C with a cone gas flow of 50 l/h, a desolvation gas  
9  
10 temperature of 300 °C and a desolvation gas flow of 500 l/h, the capillary voltage was set at 2200 V, the sample cone  
11  
12 voltage was set 30 V and the extraction cone voltage was set 3.0 V. All MS data were acquired using the LockSpray™ to  
13  
14 ensure mass accuracy and reproducibility. The mass spectrometer was calibrated using a lock-mass of leucine enkephalin at  
15  
16 a concentration of 200 pg/mL in acetonitrile (0.1% formic acid): H<sub>2</sub>O (0.1% formic acid) (50:50, v/v) for the positive ion  
17  
18 mode ( $[M+H]^+=556.2771$ ) and negative ion mode ( $[M-H]^- = 554.2615$ ) were employed at a flow rate of 100 μL min<sup>-1</sup> via a  
19  
20 lock spray interface.  
21  
22  
23  
24  
25  
26  
27

## 28 29 **2.6 Data analysis**

30  
31 Post-acquisition analyses were performed using a MetaboLynx™ (v4.1) program which is able to show the presence of a  
32  
33 wide range of metabolites, to generate a series of extracted ion chromatograms (XICs). These XICs are compared between  
34  
35 the control and sample to eliminate those chromatographic peaks in the sample that also appear in the control. The data file  
36  
37 from the dosed plasma and the control plasma was specified as 'analyte' and 'control'. Peaks presented in the analyte were  
38  
39 evaluated by their retention times compared to control sample, meanwhile, the peak area in the analyte had to be at least 5  
40  
41 times greater than that of the control. First, the acquired data were processed using a user-defined parameter file, to  
42  
43 generate a preliminary report file. Second, this report was displayed in the browser, and the output refined by a variety of  
44  
45 data filters. Finally, a large number of peaks were generated, and it was necessary to determine manually whether they were  
46  
47 likely to be compound-related metabolites.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **3. Results and discussion**

### **3.1 Analytical consideration for UPLC-Q-TOF-HDMS**

To acquire UPLC chromatograms with good separation, various chromatographic columns, mobile phases, column temperatures and flow rates that were optimized. For analysis of SMS, a Acquity UPLC<sup>®</sup> HSS T<sub>3</sub> column was found to be better than Acquity UPLC BEH c<sub>18</sub> column. It was found that a mixture of 0.01 % formic acid/H<sub>2</sub>O and 0.01 % formic acid/acetonitrile (gradient) produced better chromatographic separation for SMS, control and dosed plasma samples. The temperature and flow rate were 45 °C and 0.5 mL/min respectively for better separation. The spectrometric parameters were also optimized for max sensitivity achievement of most components. The analysis was carried out in both positive and negative mode by following the optimized MS parameters to get high responses from all compounds in MS spectra.

### **3.2 Optimization of sample preparation**

1  
2  
3  
4 Various approaches were adopted to prepare the plasma samples in order to select an efficient method to obtain a better  
5 recovery of the target compounds, such as using protein precipitation, SPE, and liquid-liquid extraction. The sensitivity of  
6 MS spectra was reduced by protein precipitants such as acetonitrile, methanol and acetone sample extracts etc., and the  
7 outcome of recovery and relative standard deviation of SPE was found better than the other method utilizations. Eventually,  
8 SPE was chosen to process the simultaneous extraction of the components and ensured less interference from the co-eluted  
9 endogenous matrices. The blood samples were collected from each rat from the hepatic portal vein at 0.25, 1, 2, 3, 5, 8 and  
10 12h after oral administration. In this experiment, peaks and responses detected in the LC-MS spectrum at 1 h post-dose  
11 were more and higher than at other points of time, which indicated the extent of SMS absorption reached maximum  
12 approximately. Therefore, LC-MS chromatography post-dose at 1h was adopted as blood collecting time to study the  
13 multiple absorbed bioactive components and metabolites in rat plasma.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 3.3. Identification of constituents of SMS in vivo by UPLC–Q-TOF/HDMS

34  
35 A significant aim for pharmaceutical discovery is the rapid screening and identification of potential bioactive compounds  
36 in TCM [17-21]. Thus, the purpose of using UPLC–ESI-Q-TOF/MS technique in this part was to discover the components  
37 absorbed. Comparing with the chromatograms between the dosed and control plasma samples to find different peaks as the  
38 components absorbed into blood including prototype (parent) compounds. Under the optimized conditions, the typical  
39 chromatograms (both in positive and negative modes) of the SMS samples are shown in Fig. 1 in selected ion monitoring  
40 (SIM) mode, including 17 components (13 in the positive mode, 4 in the negative mode) marked with numerals 1–17 in the  
41 chromatogram with a comprehensive comparison between their peaks. The components in rat plasma after oral  
42 administration of SMS were well separated and identified by using their retention time and mass spectra. From a  
43 comprehensive analysis of the chromatograms of SMS, comparing individual peak retention times and the online MS  
44 spectra with those of authentic compounds, 13 peaks were found in positive mode and 4 peaks in negative mode common  
45 both in the SMS spectra and dosed plasma spectra respectively, which demonstrated that the 17 components were absorbed  
46 into the rat's blood from SMS in the prototype. Moreover, another 13 peaks were detected using MetaboLynx software  
47 package (Waters Corp., Milford, MA, USA). Compared with the conventional manual inspection, Metabolynx analyzer in a  
48 much shorter time frame and more chemical compounds, avoiding the omission of some compounds at the lower  
49 concentration levels, and could comprehensively understand the material basis of SMS. It is concluded that a valid and  
50 robust platform based on UPLC-Q-TOF-HDMS analytical technique was established, which gives high sensitivity and  
51 resolution that is useful for identification of multiple compounds of SMS *in vivo*.  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 3.4 Structural characterization of proposed bioactive components

1  
2  
3  
4 In accordance with the optimized chromatographic and mass spectrum conditions, MassLynx V4.1 workstation is used to  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

In accordance with the optimized chromatographic and mass spectrum conditions, MassLynx V4.1 workstation is used to conduct structure analysis of chromatographic peaks in the total ion chromatogram of the transmitting components in SMS blood. Specific procedure is as the following: first of all, use the MS method to measure the precise mass of the compounds, get the element composition of corresponding compounds within the error range of measurement (less than 5ppm), and calculate the degree of un-saturation; then, search in the compound database by molecular formula or molecular mass, get possible compound structure, combine it with the MS/MS data and screen out the most possible one or several types of compounds; at last, by comparing the optimized chromatographic and mass spectrum behaviors with the reference substances, or through corresponding references, or searching in the database, confirm the compound structure. Through the structure analysis of chromatographic peaks conducted with the method mention above, we find that ginsenosides component can be tested out under the negative mode, and appears as the parent ion of  $[M+H]^-$  and  $[M-H+HCOOH]^-$ ; lignins type component can only be tested out under the positive ion mode, and appears in the form of  $[M+H]^+$ ,  $[M+H-H_2O]^+$  and  $[M+Na]^+$ . According to the standards and data recorded in literature, we had identified the 30 peaks of prototype components and metabolites. Fig.2A showed the MS spectra of reference substance ginsenoside Rh1. Fig.2B showed the MS/MS information and structure analyzing process of ginsenoside Rh1, which represented for ginsenosides. According to the mass spectra and fragment assignment at high collision energy (Fig.3A), the low collision (Fig.3B) and proposed fragmentation pathways (Fig.3C) in positive mode, the compound was identified as Schisantherin A. Similarly, other compounds could also be characterized according to the above-mentioned methods.

### 3.5 Application of MetaboLynx to analysis compounds in vivo

Based on the above parameters, the UPLC-Q-TOF-HDMS chromatograms were processed under positive and negative mode by the application of Metabolynx respectively. After the good filtering of each peak in mass spectrum, background interferences were removed, and the blood component peaks was easily to identify, meanwhile, the extracted ions were listed in the window 'Expected Metabolites' according to the isotope peaks and fragment ions for further manual investigation. Metabolynx can be used to extract the internal composition and metabolite of TCM. It can target screening the metabolites in accordance with the set metabolic pathway, and give potential compounds to be screened in accordance with other known metabolic pathways, and in this way realizing the purpose of holographic testing. Application of Meyabolynx, 13 compounds were screened out besides the intuitional comparison shown in table 1. Chemical compositions of the same type in TCM has similar biological resources and pathways, and also has similar metabolic processes within the body.

Several analytical methods have been established to purify and indentify the metabolites from TCM *in vivo* [22-26]. In the current study, mass spectrometry along with UPLC was used to identify SMS chemicals and metabolites in plasma. Given its high sensitivity and reliability, this approach should then be applied to investigate the chemicals composition of other

1  
2  
3  
4 herbal remedies along with their metabolites. This work could provide a scientific basis for elevating the quality of herbs  
5  
6 and their compound preparations and optimizing the dosage regimens, as well as contributing the knowledges of searching  
7  
8 active metabolites for drug discovery. In addition, the method could be developed as an integrated template approach to  
9  
10 analysis for screening and identification of the bioactive components in blood after oral administration of herb and  
11  
12 provided helpful chemical information for further pharmacology and active mechanism research on TCM.  
13  
14  
15  
16  
17  
18  
19

#### 20 21 **4. Conclusion**

22  
23 In this paper, we described a method using UPLC–Q-TOF/HDMS with automated data analysis (Metabolynx™) for fast  
24  
25 analysis of metabolic profile of SMS in rat plasma after oral administration. It provides unique high throughput capabilities  
26  
27 for drug metabolism study, with excellent MS accuracy and enhanced data acquisition. A total 30 compounds including 23  
28  
29 prototype components and 7 metabolites were successfully separated and characterized tentatively. This method could  
30  
31 provide a rapid and valid platform for identification of multiple components for TCM. This identification and structural  
32  
33 elucidation of the constituents in SMS and rat plasma provided essential data for further active chemical constituents  
34  
35 identification and pharmacological research of SMS. It would be also helpful to better understand the pharmacodynamic  
36  
37 profile of SMS, which will facilitate its clinical usage and quality control during production.  
38  
39  
40  
41  
42  
43  
44  
45  
46

#### 47 48 **Acknowledgments**

49  
50 This work was supported by grants from the Key Program of Natural Science Foundation of State (Grant No. 90709019,  
51  
52 81430093, 81173500, 81373930, 81302905, 81102556, 81202639), National Key Technology Research and Development  
53  
54 Program of the Ministry of Science and Technology of China (Grant No. 2011BAI03B03, 2011BAI03B06,  
55  
56 2011BAI03B08).  
57  
58  
59  
60

#### **Competing financial interests**


The authors declare no competing financial interests.

**References**


- 1 Wang X, Zhang A, Sun H. Future perspectives of Chinese medical formulae: chinmedomics as an effector. *OMICS*. 2012;16(7-8):414-21.
- 2 Zhao X, Long Z, Dai J, Bi K, Chen X. Identification of multiple constituents in the traditional Chinese medicine formula Zhi-zi-chi decoction and rat plasma after oral administration by liquid chromatography coupled to quadrupole time-of-flight tandem mass spectrometry. *Rapid Commun Mass Spectrom*. 2012;26(20):2443-53.
- 3 Zhang A, Sun H, Qiu S, Wang X. Advancing drug discovery and development from active constituents of yinchenhao tang, a famous traditional chinese medicine formula. *Evid Based Complement Alternat Med*. 2013;2013:257909.
- 4 Zhang A, Sun H, Wang X. Potentiating therapeutic effects by enhancing synergism based on active constituents from traditional medicine. *Phytother Res*. 2014;28(4):526-33.
- 5 Zhang A, Sun H, Wang X, Jiao G, Yuan Y, Sun W. Simultaneous in vivo RP-HPLC-DAD quantification of multiple-component and drug-drug interaction by pharmacokinetics, using 6,7-dimethylesculetin, geniposide and rhein as examples. *Biomed Chromatogr*. 2012;26:844-850.
- 6 Wang X, Sun H, Zhang A, Jiao G, Sun W, Yuan Y. Pharmacokinetics screening for multi-components absorbed in the rat plasma after oral administration traditional Chinese medicine formula Yin-Chen-Hao-Tang by ultra performance liquid chromatography-electrospray ionization/quadrupole-time-of-flight mass spectrometry combined with pattern recognition methods. *Analyst*. 2011;136:5068-5076..
- 7 Sun H, Wu F, Zhang A, Wei W, Han Y, Wang X. Profiling and identification of the absorbed constituents and metabolites of schisandra lignans by ultra-performance liquid chromatography coupled to mass spectrometry. *Biomed Chromatogr*. 2013;27(11):1511-9.
8. Xu N, Qiu C, Wang W, Wang Y, Chai C, Yan Y, Zhu D. HPLC/MS/MS for quantification of two types of neurotransmitters in rat brain and application: myocardial ischemia and protection of Sheng-Mai-San. *J Pharm Biomed Anal*. 2011;55(1):101-8
9. Wang YQ, Zhang JQ, Liu CH, Zhu DN, Yu BY. Screening and identifying the myocardial-injury protective ingredients from Sheng-Mai-San. *Pharm Biol*. 2013;51(10):1219-27.
10. Wu F, Sun H, Wei W, Han Y, Wang P, Dong T, Yan G, Wang X. Rapid and global detection and characterization of the constituents in ShengMai San by ultra-performance liquid chromatography-high-definition mass spectrometry. *J Sep Sci*. 2011;34(22):3194-9.
11. Wang YH, Qiu C, Wang DW, Hu ZF, Yu BY, Zhu DN. Identification of multiple constituents in the traditional Chinese medicine formula Sheng-Mai San and rat plasma after oral administration by HPLC-DAD-MS/MS. *J Pharm Biomed Anal*. 2011;54(5):1110-27.

- 1  
2  
3  
4 12. Yang B, Dong W, Zhang A, Sun H, Wu F, Wang P, Wang X. Ultra-performance liquid chromatography coupled with  
5 electro spray ionization/quadrupole-time-of-flight mass spectrometry for rapid analysis of constituents of Suanzaoren  
6 decoction. *J Sep Sci.* 2011;34(22):3208-15.  
7  
8  
9  
10  
11 13. Wang X, Sun H, Zhang A, Jiao G, Sun W, Yuan Y. Pharmacokinetics screening for multi-components absorbed in the  
12 rat plasma after oral administration traditional Chinese medicine formula Yin-Chen-Hao-Tang by ultra performance liquid  
13 chromatography-electrospray ionization/quadrupole-time-of-flight mass spectrometry combined with pattern recognition  
14 methods. *Analyst.* 2011;136(23):5068-76.  
15  
16  
17  
18 14. Yin Q, Sun H, Zhang A, Wang X. Pharmacokinetics and tissue distribution study of scoparone in rats by  
19 ultraperformance liquid-chromatography with tandem high-definition mass spectrometry. *Fitoterapia.* 2012;83(4):795-800.  
20  
21  
22  
23 15. Sun H, Yin Q, Zhang A, Wang X. UPLC-MS/MS performing pharmacokinetic and biodistribution studies of rhein. *J*  
24 *Sep Sci.* 2012;35(16):2063-8.  
25  
26  
27  
28 16. Sun H, Wu F, Zhang A, Wei W, Han Y, Wang X. Pharmacokinetic study of schisandrin, schisandrol B, schisantherin A,  
29 deoxyschisandrin, and schisandrin B in rat plasma after oral administration of Shengmaisan formula by UPLC-MS. *J Sep*  
30 *Sci.* 2013;36(3):485-91.  
31  
32  
33  
34 17. Zhang YY, Wang Q, Qi LW, Qin XY, Qin MJ. Characterization and determination of the major constituents in  
35 *Belamcandae Rhizoma* by HPLC-DAD-ESI-MS(n). *J Pharm Biomed Anal.* 2011 Sep 10;56(2):304-14.  
36  
37  
38  
39 18. Cao H, Chen X, Sun H, Sakurai T, Zhou J, Sun W, Lv H, Wang X. Pharmacokinetics-based elucidation on disparity in  
40 clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula. *J Ethnopharmacol.*  
41 2010;128:606-610.  
42  
43  
44  
45 19. Cao G, Cai H, Zhang Y, Cong X, Zhang C, Cai B. Identification of metabolites of crude and processed *Fructus Corni* in  
46 rats by microdialysis sampling coupled with electrospray ionization linear quadrupole ion trap mass spectrometry. *J Pharm*  
47 *Biomed Anal.* 2011;56(1):118-25.  
48  
49  
50  
51 20. Wang H, Sun H, Zhang A, Li Y, Wang L, Shi H, Dizou XL, Wang X. Rapid identification and comparative analysis of  
52 the chemical constituents and metabolites of *Phellodendri amurensis* cortex and Zhibai dihuang pill by ultra-performance  
53 liquid chromatography with quadrupole TOF-MS. *J Sep Sci.* 2013;36(24):3874-82.  
54  
55  
56  
57 21. Zhang A, Zou D, Yan G, Tan Y, Sun H, Wang X. Identification and characterization of the chemical constituents of  
58 Simiao Wan by ultra high performance liquid chromatography with mass spectrometry coupled to an automated multiple  
59 data processing method. *J Sep Sci.* 2014;37(14):1742-7.  
60  
61  
62  
63 22. Wen XD, Liu EH, Yang J, Li CY, Gao W, Qi LW, Wang CZ, Yuan CS, Li P. Identification of metabolites of Buyang  
Huanwu decoction in rat urine using liquid chromatography-quadrupole time-of-flight mass spectrometry. *J Pharm Biomed*  
*Anal.* 2012;67-68:114-22.


- 1  
2  
3  
4 23. Xue C, Jiang S, Guo J, Qian D, Duan JA, Shang E. Screening for in vitro metabolites of *Abelmoschus manihot* extract  
5  
6 in intestinal bacteria by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. *J*  
7  
8 *Chromatogr B Analyt Technol Biomed Life Sci.* 2011;879(32):3901-8.  
9  
10  
11 24. Zhang A, Sun H, Wang X, Jiao G, Yuan Y, Sun W. Simultaneous in vivo RP-HPLC-DAD quantification of  
12  
13 multiple-component and drug-drug interaction by pharmacokinetics, using 6,7-dimethylesculetin, geniposide and rhein as  
14  
15 examples. *Biomed Chromatogr.* 2012;26(7):844-50.  
16  
17  
18 25. Wang H, Yan G, Zhang A, Li Y, Wang Y, Sun H, Wu X, Wang X. Rapid discovery and global characterization of  
19  
20 chemical constituents and rats metabolites of *Phellodendri amurensis* cortex by ultra-performance liquid  
21  
22 chromatography-electrospray ionization/quadrupole-time-of-flight mass spectrometry coupled with pattern recognition  
23  
24 approach. *Analyst.* 2013;138(11):3303-12.  
25  
26  
27 26. Clifford MN, Wu W, Kirkpatrick J, Jaiswal R, Kuhnert N. Profiling and characterisation by liquid  
28  
29 chromatography/multi-stage mass spectrometry of the chlorogenic acids in *Gardeniae Fructus*. *Rapid Commun Mass*  
30  
31 *Spectrom.* 2010;24(21):3109-20.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Fig.1** The UPLC-Q-TOF-HDMS chromatograms of the sample in rat serum after oral administration of SMS in the positive (up) and negative (down) ion mode.



**Fig.2.** MS spectra of reference substance ginsenoside Rh1 (A) and MS/MS information and structure analyzing process of Ginsenoside Rh1(Peak14) (B).



**Fig.3** The mass spectra of Schisantherin A in positive mode.

The mass spectra and fragment assignment at high collision energy (A); the mass spectrum at low collision (B); proposed fragmentation pathways of Schisantherin A (C).

**Table 1.** The constituents in rat serum after oral administration of SMS

Peak No.	Rt (min)	Name	Molecular formula	Molecular Weight	[M+Na] <sup>+</sup> / [M-H] <sup>-</sup>	Error (ppm)
1	5.86	7,8-dihydroxy-3-demethyl schizandrin ☆	C <sub>23</sub> H <sub>30</sub> O <sub>8</sub>	434.4795	457.1823	-3.3
2	6.31	7,8-dihydroxy-2-demethyl schizandrin ☆	C <sub>23</sub> H <sub>30</sub> O <sub>8</sub>	434.4795	457.1826	-2.6
3	6.46	7,8-dihydroxy-2-demethyl schizandrin isomer☆	C <sub>23</sub> H <sub>30</sub> O <sub>8</sub>	434.4795	457.1830	-1.7
4	7.91	7,8-dihydroxy-schizandrin ☆	C <sub>24</sub> H <sub>30</sub> O <sub>7</sub>	448.5061	471.1987	-1.7
5	9.94	Schisandrin	C <sub>24</sub> H <sub>32</sub> O <sub>7</sub>	432.5067	455.2035	-2.4
6	10.45	Gominsin D	C <sub>28</sub> H <sub>34</sub> O <sub>10</sub>	530.5636	553.2035	-2.7
7	10.83	Schisandrol B	C <sub>23</sub> H <sub>28</sub> O <sub>7</sub>	416.4642	439.1729	1.3
8	12.34	Angeloygomisin H	C <sub>23</sub> H <sub>28</sub> O <sub>6</sub>	500.5806	523.2306	-0.4
9	13.66	Schisantherin A	C <sub>30</sub> H <sub>32</sub> O <sub>9</sub>	536.5697	559.1939	-0.9
10	13.78	Schisantherin B	C <sub>24</sub> H <sub>32</sub> O <sub>6</sub>	514.5642	537.2092	-1.7
11	15.42	Deoxyschisandrin	C <sub>23</sub> H <sub>28</sub> O <sub>6</sub>	416.5073	439.2085	-2.7
12	15.89	γ-Schisandrin	C <sub>23</sub> H <sub>28</sub> O <sub>6</sub>	400.4648	423.1779	-1.2
13	16.05	Schisandrin B	C <sub>36</sub> H <sub>62</sub> O <sub>9</sub>	400.4648	423.1789	1.2
14	7.56	20(S)-Ginsenoside Rh1	C <sub>36</sub> H <sub>62</sub> O <sub>9</sub>	638.8721	637.4310	-0.9
15	7.81	20(R)-Ginsenoside Rh1	C <sub>36</sub> H <sub>60</sub> O <sub>8</sub>	638.8721	637.4326	1.6
16	10.37	Ginsenoside Rk3	C <sub>36</sub> H <sub>60</sub> O <sub>8</sub>	620.8568	619.4210	-0.5
17	10.66	Ginsenoside Rh4	C <sub>24</sub> H <sub>32</sub> O <sub>6</sub>	620.8568	619.4233	3.7
18	6.60	Gomisin P isomer ☆	C <sub>23</sub> H <sub>28</sub> O <sub>8</sub>	432.4636	455.1674	-1.8
19	8.02	Gomisin H isomer ☆	C <sub>23</sub> H <sub>30</sub> O <sub>7</sub>	418.4801	441.1889	1.1
20	8.98	Isoschisandrin	C <sub>24</sub> H <sub>32</sub> O <sub>7</sub>	432.5067	455.2075	1.1
21	9.65	Schisandrin isomer ☆	C <sub>24</sub> H <sub>32</sub> O <sub>7</sub>	432.5067	455.2029	-3.7
22	10.99	Unknown	C <sub>27</sub> H <sub>32</sub> O <sub>9</sub>	500.5376	523.1945	0.2
23	11.28	Unknown	C <sub>28</sub> H <sub>36</sub> O <sub>10</sub>	532.5794	555.2202	0.7
24	11.48	Unknown	C <sub>28</sub> H <sub>36</sub> O <sub>10</sub>	532.5794	555.2198	-1.4
25	11.75	Tigloylgomisin H	C <sub>28</sub> H <sub>36</sub> O <sub>8</sub>	500.5806	523.2295	-2.5
26	12.39	Epi-Gomisin O	C <sub>23</sub> H <sub>28</sub> O <sub>7</sub>	416.4642	439.1728	-1.1
27	12.63	Benzoylgomisin Q	C <sub>31</sub> H <sub>36</sub> O <sub>9</sub>	552.6121	575.2265	1.4
28	12.84	Angeloylgomisin Q	C <sub>29</sub> H <sub>38</sub> O <sub>9</sub>	530.6066	553.2419	0.9
29	13.49	Gomisin F	C <sub>28</sub> H <sub>34</sub> O <sub>9</sub>	514.5642	537.2095	-1.1
30	16.32	Schisandrin C	C <sub>22</sub> H <sub>24</sub> O <sub>6</sub>	384.4224	407.1473	0.5

Note: ☆, metabolite